504 related articles for article (PubMed ID: 26019183)
1. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
Clin Chem; 2015 Jun; 61(6):850-69. PubMed ID: 26019183
[TBL] [Abstract][Full Text] [Related]
2. Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney GR; Huestis MA
Clin Chem; 2016 Feb; 62(2):367-77. PubMed ID: 26823611
[TBL] [Abstract][Full Text] [Related]
3. Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
Newmeyer MN; Swortwood MJ; Barnes AJ; Abulseoud OA; Scheidweiler KB; Huestis MA
Clin Chem; 2016 Dec; 62(12):1579-1592. PubMed ID: 27899456
[TBL] [Abstract][Full Text] [Related]
4. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ
Newmeyer MN; Swortwood MJ; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
Clin Chem; 2017 Mar; 63(3):647-662. PubMed ID: 28188235
[TBL] [Abstract][Full Text] [Related]
5. Cannabis effects on driving lateral control with and without alcohol.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
Drug Alcohol Depend; 2015 Sep; 154():25-37. PubMed ID: 26144593
[TBL] [Abstract][Full Text] [Related]
6. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):690-701. PubMed ID: 26257143
[TBL] [Abstract][Full Text] [Related]
7. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.
Swortwood MJ; Newmeyer MN; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
Drug Test Anal; 2017 Jun; 9(6):905-915. PubMed ID: 27647820
[TBL] [Abstract][Full Text] [Related]
10. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.
Lee D; Bergamaschi MM; Milman G; Barnes AJ; Queiroz RH; Vandrey R; Huestis MA
J Anal Toxicol; 2015 Oct; 39(8):580-7. PubMed ID: 26378131
[TBL] [Abstract][Full Text] [Related]
11. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
[TBL] [Abstract][Full Text] [Related]
12. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.
Marsot A; Audebert C; Attolini L; Lacarelle B; Micallef J; Blin O
J Pharm Pharm Sci; 2016; 19(3):411-422. PubMed ID: 27806250
[TBL] [Abstract][Full Text] [Related]
14. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
[TBL] [Abstract][Full Text] [Related]
15. Cannabis effects on driving longitudinal control with and without alcohol.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Pierce RS; Gorelick DA; Gaffney G; Huestis MA
J Appl Toxicol; 2016 Nov; 36(11):1418-29. PubMed ID: 26889769
[TBL] [Abstract][Full Text] [Related]
16. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
[TBL] [Abstract][Full Text] [Related]
17. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
Schwope DM; Karschner EL; Gorelick DA; Huestis MA
Clin Chem; 2011 Oct; 57(10):1406-14. PubMed ID: 21836075
[TBL] [Abstract][Full Text] [Related]
18. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
19. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.
Vandrey R; Herrmann ES; Mitchell JM; Bigelow GE; Flegel R; LoDico C; Cone EJ
J Anal Toxicol; 2017 Mar; 41(2):83-99. PubMed ID: 28158482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
